CHRONIC VAS UTILIZING AXIAL FLOW BLOOD PUMP

拟议活动的长期目标是开发和营销 一种基于直接电机驱动轴向解剖相容的慢性VAS 流动血泵。第一阶段研究的具体目标是 同时展示机械完整性和血液密封性能 该装置具有良好的水力和溶血性能。这个 第二阶段的体外和体内试验旨在证明耐力 能力、溶血、性能和抗血栓形成特性 通过体外耐力和体内慢性耐力测试。协议用于 第一阶段将模拟以前为轴向流动开发的模型 外围引进的血液泵，目前正在进行临床 审判。 技术创新涉及25cc可植入的慢性VAS 体积基于演示的轴流血液泵送技术。其他 VAS的要素；马达、马达控制、经皮通道和 支撑包在慢性NHLBI VAS研究中具有雄厚的技术基础。 商业潜力的基础是种植体体积小和较低 与传统循环输送装置相比，VAS的成本更高。

The long-term objective of the proposed activity is to develop, and market an anatomically compatible chronic VAS based on a direct motor driven axial flow blood pump. The specific aim of the Phase I research is to demonstrate the mechanical integrity and blood seal performance together with satisfactory hydraulic and hemolysis performance of the device. The Phase II in vitro and in vivo testing is designed to demonstrate endurance capability, hemolysis, performance and antithrombogenic characteristics through in vitro endurance and chronic in vivo testing. Protocols for Phase I will model those previously developed for the axial flow peripherally introduced Hemopump, which is currently undergoing clinical trials. The technical innovation involves a chronic VAS with a 25cc implantable volume based on demonstrated axial flow blood pumping technology. Other elements of the VAS; the motor, motor controls, percutaneous access and the support pack have a strong technology base in chronic NHLBI VAS research. The commercial potential is based on the small implant volume and lower cost of the VAS compared to conventional cyclic delivery devices.